← Back to patent-cliff list
FB-849
Tier C — Watch / tradeFB-849
1st Biotherapeutics Inc
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：MAP4K1
Indications (approved)：Solid tumour, Neoplasm
Regional status
US
Phase II
2023-12-13
EU
-
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of FB-849?
Approved indications include: Solid tumour, Neoplasm.
When does the FB-849 patent expire?
No public expiry year is available for FB-849 yet; this page updates once verified.
How do I get a quote for FB-849 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-02